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ABSTRACT
Introduction Blood pressure (BP) is normally measured 
on the upper arm, and guidelines for the diagnosis and 
treatment of high BP are based on such measurements. 
Leg BP measurement can be an alternative when brachial 
BP measurement is impractical, due to injury or disability. 
Limited data exist to guide interpretation of leg BP values 
for hypertension management; study- level systematic 
review findings suggest that systolic BP (SBP) is 17 mm 
Hg higher in the leg than the arm. However, uncertainty 
remains about the applicability of this figure in clinical 
practice due to substantial heterogeneity.
Aims To examine the relationship between arm and leg 
SBP, develop and validate a multivariable model predicting 
arm SBP from leg SBP and investigate the prognostic 
association between leg SBP and cardiovascular disease 
and mortality.
Methods and analysis Individual participant data (IPD) 
meta- analyses using arm and leg SBP measurements 
for 33 710 individuals from 14 studies within the 
Inter- arm blood pressure difference IPD (INTERPRESS- 
IPD) Collaboration. We will explore cross- sectional 
relationships between arm and leg SBP using hierarchical 
linear regression with participants nested by study, in 
multivariable models. Prognostic models will be derived for 
all- cause and cardiovascular mortality and cardiovascular 
events.
Ethics and dissemination Data originate from studies 
with prior ethical approval and consent, and data sharing 
agreements are in place—no further approvals are 
required to undertake the secondary analyses proposed 
in this protocol. Findings will be published in peer- 
reviewed journal articles and presented at conferences. 
A comprehensive dissemination strategy is in place, 
integrated with patient and public involvement.
PROSPERO registration number CRD42015031227.
INTRODUCTION
Blood pressure (BP) is normally measured 
on the upper arm, and all guidelines for the 
Strengths and limitations of this study
 ► This individual participant data (IPD) meta- analysis 
uses the INTERPRESS- IPD Collaboration (IPD from 
24 international cohorts, originally created to ex-
plore the association between interarm differences 
in blood pressure (BP) and mortality risk), the largest 
known dataset to allow an in- depth exploration of 
the relationship between arm and leg systolic BP 
(SBP) and the role of leg SBP in cardiovascular risk 
estimation.
 ► An IPD approach maximises statistical power and 
allows a consistent approach toward all available 
data that cannot be achieved with study- level 
meta- analyses.
 ► Inclusion of a number of international cohorts in this 
IPD meta- analyses will maximise the generalisabil-
ity of the findings.
 ► Methods of data collection and reporting of results 
vary between included cohorts and this is acknowl-
edged as a limitation of the data. We are aware of 
other studies with arm and leg BP data that are 
not included in the INTERPRESS- IPD Collaboration. 
However, the dataset is large enough to allow ro-
bust analysis and sufficient subgroup and sensitivity 
analyses to answer questions that cannot be ad-
dressed by study- level meta- analyses.
 ► Patient and public involvement (PPI) activities have 
been, and will be, undertaken throughout every 
stage of this project and we include three PPI advi-
sors and a PPI facilitator as coauthors.
 on M









pen: first published as 10.1136/bm





2 McDonagh STJ, et al. BMJ Open 2021;11:e040481. doi:10.1136/bmjopen-2020-040481
Open access 
diagnosis and treatment of high BP are based on such 
measurements.1–3 When brachial BP measurement is not 
possible, other measurement sites are required. Uncer-
tainty over interpretation of non- brachial BP measure-
ment may result in inaccurate BP estimates, leading to 
suboptimal management of hypertension, risking avoid-
able cerebrovascular or ischaemic cardiac events.4 In 
the clinical setting, this may be a temporary problem 
due, for example, to fractures, wounds, vascular access 
devices or during surgical procedures. However, for 
some people, there are permanent barriers to brachial 
BP measurement, such as amputation, bilateral lymphoe-
dema (eg, after bilateral mastectomy for breast cancer) 
or phocomelia (eg, secondary to thalidomide).5 Brachial 
BP measurement may also be inaccurate, and difficult 
to self- administer, where there is altered muscle tone or 
hemiplegia following stroke.6 7 It is also unreliable in the 
presence of bilateral subclavian, axillary or brachial artery 
stenoses due to atheroma or arteritides.8 In any of these 
circumstances, measurement of BP in the leg is a suitable 
alternative for monitoring BP, diagnosing and treating 
hypertension. However, at present, only limited data exist 
to guide interpretation of the leg systolic BP (SBP) values.
Historically, ranges of 10–40 mm Hg have been 
suggested for the difference (ie, leg minus arm) between 
SBP measured in the arm and leg in healthy individuals.9 10 
Recently, a systematic review and study level meta- analysis 
of observational studies were published examining this 
relationship.11 Based on 44 included studies, totalling 
9771 participants, ankle SBP was found to be 17.0 mm 
Hg (95% CIs 15.4 to 21.3 mm Hg) higher than arm BP 
in the general population; for diastolic BP, there was no 
difference. These findings suggested that a threshold of 
155/90 mm Hg in the leg (equating to the National Insti-
tute for Health and Care Excellence (NICE) threshold of 
140/90 mm Hg in the arm)3 might be used for diagnosing 
hypertension when ankle BPs are the only measure-
ments available. However, significant statistical hetero-
geneity was observed in all analyses, which could not be 
explained in subgroup or sensitivity analyses according 
to cardiovascular disease history, cardiovascular disease 
risk, measurement method and device or methodological 
quality. Metaregression by age and arm SBP level was also 
uninformative.11
Study- level aggregate meta- analyses are limited in the 
conclusions that can be drawn, because they combine 
studies with different patient characteristics (eg, age 
or coexisting disease), methodological choices (eg, 
posture in BP measurement or sequential vs simulta-
neous measurement) and analytical approaches. These 
limitations can potentially be overcome by obtaining the 
original individual participant data (IPD) from cohorts.12 
Such IPD meta- analyses, while time consuming, offer 
advantages, such as checking of modelling assumptions, 
analysing variables on continuous scales and the possi-
bility of assessing for non- linear relationships.13 They 
offer the ability to uniformly adjust findings for other 
variables, thus potentially accounting and adjusting for 
heterogeneity between findings in a way that study- level 
meta- analyses cannot.14
We propose to undertake IPD meta- analyses to answer 
the following research questions:
1. What is the mean difference, in the absence of periph-
eral arterial disease, between SBP measured in the arm 
and SBP measured in the leg in the same individuals?
2. To what extent do these differences vary according to 
patient characteristics and methods of measurement, 
and what are the impacts of cerebrovascular and car-
diac diseases on the difference between arm and leg 
pressures?
3. Can a model be developed and validated to predict 
arm SBP, based on leg SBP measurements and other 
patient characteristics, to inform interpretation of in-
dividual leg SBP readings?
4. How does leg BP, in comparison with models based 




This IPD meta- analysis has the following aims
1. To examine the relationship between arm and leg SBP, 
taking into account patient characteristics such as age, 
baseline BP and medical history.
2. To derive and validate a prediction model to permit 
estimation of an equivalent brachial SBP based on leg 
SBP measurements.
3. To determine the independent prognostic value of leg 
SBP in predicting cardiovascular events and mortality 
risk.
Data sources and description of the dataset
This study will use an observational cohort design, under-
taking IPD meta- analyses of data held by the interarm 
BP difference (INTERPRESS- IPD) Collaboration, estab-
lished to undertake IPD meta- analyses examining the 
independent contribution of interarm BP difference to 
prediction of mortality and cardiovascular events.15 The 
establishment of the Collaboration has been previously 
described.15 In brief, literature searches and author 
contacts were used to identify studies likely to hold 
records of BP in both arms. A subset of these studies 
measured Ankle–Brachial Index (ABI) at recruitment, 
thus providing data for arm and leg BPs.16 Individual data 
sharing agreements are in place with the lead authors of 
each participating study; their consent has been obtained 
for the proposed analyses and corresponding authors 
for each participating study will contribute to publica-
tions arising from these analyses. Core data, held for the 
primary INTERPRESS- IPD research outputs, will undergo 
additional cleaning and merging of relevant additional 
variables prior to combination into a new, expanded, 
single dataset.
The new Arm Based on LEg- BP (ABLE- BP) dataset 
will include 33 710 individual records from 14 European, 
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USA and African studies that measured both arm and leg 
BP. Participants in the dataset have a mean age of 58 years 
(range: 18–99 years), 45% are women and mean systolic/
diastolic brachial BP is 135/80 mm Hg. In total, 20 191 
(60 %) have hypertension (defined as a formal clinical 
diagnosis and/or on antihypertensive treatment), 4917 
(15 %) have diabetes, 5474 (17 %) have pre- existing 
ischaemic heart disease and 1900 (6 %) have had a cere-
brovascular event. Median follow- up period is 8.0 years, 
with 2811 (9 %) participants experiencing cardiovascular 
events or death and 621 (2 %) dying within 10 years. We 
will present tables including descriptors (eg, country, 
method of BP measurement, description of cohort) 
of each study to assess comparability and describe the 
dataset. A summary of the included studies and their 
characteristics is given in table 1.
Outcomes
The primary outcome (systolic arm- leg BP difference) 
for the analyses will be defined as the lower leg posterior 
tibial artery BP minus the higher arm BP measured on the 
brachial artery. The coprimary outcome will be arm SBP 
predicted from leg BP. Primary analyses will use observed 
data only (see missing data—below).
Secondary outcomes are the prognostic value of leg BPs 
for prediction of cardiovascular events and mortality.
Quality assessment
The methodological quality and risk of bias for studies 
contributing data has been assessed using the Quality 
assessment In Prognostic Studies (QUIPS) score, modi-
fied for IPD analysis.17 These assessments will be used to 
inform sensitivity analyses focusing on the highest quality 
studies. This quality assessment covers domains on selec-
tion bias, attrition, and accuracy of measurement, analysis 
and confounding.
Participant selection
Participants with ankle or arm BP missing at recruitment 
will be excluded from the analyses. We will also exclude 
participants with a diagnosis of peripheral arterial disease, 
low ABI (<0.90) and those studies where participant entry 
criteria was based on selected ABI.
Statistical analysis
Descriptive analyses
Descriptive statistics will be used to describe participant 
characteristics at the study level, including age, sex, 
ethnic group, body mass index (BMI), arm and leg BP, 
and history of cardiovascular diseases (and risk factors). 
Data will be presented as means with SD, median with 
IQR or proportions.
Investigation of relationship between leg and arm BP
We will report the mean arm- leg differences for each study. 
These will be examined in a two- stage meta- analysis. Esti-
mates of heterogeneity from these analyses will be used to 
determine whether to conduct a further one- stage anal-
ysis with study entered as a random or as a fixed effect. 
We will explore cross- sectional relationships between 
arm and leg BP in univariable and multivariable models 
with all available data, using hierarchical linear regres-
sion. Estimates will be adjusted for age, sex, baseline BP, 
smoking status, serum cholesterol and medical history at 
recruitment. Recording of medication use varies across 
cohorts; we will perform secondary analyses that include 
use of specific classes of antihypertensive medication 
(eg, calcium channel blockers, renin- angiotensin system 
blockers) using data from only those studies that recorded 
the relevant information. Should drug use be a significant 
predictor of outcome when included with other signifi-
cant variables, it will be retained in the models derived 
from these secondary analyses. Depending on the results 
of our quality assessment of primary studies, we will 
perform sensitivity analyses to include only those studies 
evaluated to be at low risk of bias. No further secondary 
or sensitivity analyses are planned.
Prediction modelling of arm BP using leg BP
Using a subset of participants with complete case data for 
candidate variables both identified above, and set a priori, 
we will model brachial SBP on leg SBP using random 
effects meta- analysis models. We will use one- stage and 
two- stage methods, and assess heterogeneity using the I2 
and tau2 statistics. One- stage models will comprise hier-
archical linear regression models (participants nested 
by study). Further models will investigate the association 
between arm- leg difference and participant character-
istics (using a series of models with one characteristic 
per model). Predictor variables to be included a priori 
in the modelling will include age, sex, BMI, smoking 
status, ethnicity, diagnosis of diabetes, hypertension or 
any cardiovascular disease, total cholesterol and baseline 
ankle BP.
The predictive model for arm SBP will be developed 
using one- stage meta- analysis with hierarchical linear 
regression models, as described above. We will derive the 
model using a subset of the complete case data (deriva-
tion dataset) and validate the model using the remaining 
data (validation dataset).18 The primary studies will be 
allocated to the derivation or validation datasets such that 
both datasets include participants of both genders and 
reflect the geographical origin of the studies.
Prognostic modelling
Prognostic models based on leg SBP will be derived for 
all- cause and cardiovascular mortality and fatal or non- 
fatal cardiovascular events. Heterogeneity will be assessed 
using I2 and tau2. We will aim to perform one- stage 
random effects time- to- event models based on flexible 
parametric models; should such models fail to converge, 
we will use fixed effect Cox proportional hazards models, 
stratified by study. Using the covariates described above, 
and again dividing the dataset into a derivation and 
validation cohort, we will derive and validate a suitable 
model. For prognostic modelling, we will exclude partici-
pants with any pre- existing cardiovascular disease.
 on M
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Using internationally recognised 10- year risk scores, 
such as the European Systematic COronary Risk Evalua-
tion (SCORE) and Atherosclerotic Cardiovascular Disease 
(ASCVD) pooled cohort equations, we will compare the 
outcome of such cardiovascular risk scores using arm 
based on leg SBP data with the actual arm SBP data.19–22 
Besides their wide use in clinical practice, these two scores 
have been selected to assess two different outcomes, as 
SCORE predicts cardiovascular mortality, while ASCVD 
predicts fatal and non- fatal cardiovascular events (cardio-
vascular death, non- fatal MI and stroke). Model goodness 
of fit will be compared using the likelihood ratio test, the 
Akaike Information Criterion,23 and for time- to- event 
models, the Harrell’s C statistic.
Missing data and sensitivity analyses
For all included studies, the primary analyses will use 
observed data only. Participants from other cohorts 
included within the INTERPRESS- IPD Collaboration lack 
leg BP data but do have brachial BP measurements and 
ABIs. We will explore whether accurate back- calculation 
of leg pressures is feasible using these data. To achieve 
this, we will establish a clear understanding of the study 
formulae used to derive ABI, including discussion with 
authors as necessary. We will then trial this approach 
using datasets that do contain leg pressures to confirm 
validity. If feasible, we will back- calculate missing leg 
SBPs and add these data to the observed data for sensi-
tivity analyses to check the primary models. We will also 
perform sensitivity analyses incorporating height into the 
final models, where available. Further sensitivity analyses, 
using multiple imputation of arm and/or leg SBP and 
participant data for the one- stage meta- analyses where 
arm- leg or arm SBP is the outcome, and for the time- 
to- event analyses will also be undertaken. The results of 
these models will be compared with the primary outcome 
models using observed data only. Finally, we will repeat 
the primary analyses excluding studies deemed to be of 
low or moderate quality based on modified QUIPS scores.
Publication and inclusion bias
Inclusion bias will be assessed by comparing our pooled 
estimate of the mean arm—leg SBP difference for studies 
included in the ABLE- BP analyses with studies using 
sequential BP measurement methods in our previous 
study- level systematic review using a two- stage meta- 
analysis.11 Publication bias will not be assessed; we believe 
that there is limited potential for publication bias, as the 
primary studies from which we derive data were not orig-
inally designed to compare arm and leg BPs. Although 
we are performing secondary analyses in a subset of an 
established dataset (INTERPRESS- IPD Collaboration), 
which is an efficient and cost- effective approach, we must 
acknowledge that the INTERPRESS- IPD dataset was not 
established for the purpose of defining the arm- leg SBP 
relationship and therefore there is a possibility that other 
data exist that fall outside the scope of the original search 
terms.
Patient and public involvement
The development of this protocol has had considerable 
patient and public involvement (PPI). Prior to funding, 
a draft was reviewed by three public advisors improving 
the overall clarity in general, and in specific areas, such 
as focussing the research questions on aspects of arm and 
leg BP that interest users. We convened two prefunding 
PPI workshops to raise awareness about involvement 
in systematic reviews and gain critical feedback for the 
project. This feedback resulted in a clearer definition of 
the population being studied, greater clarity about bene-
fits for patients and reinforcement of our user dissemi-
nation plans. We have established a PPI advisory group 
for the project, led by KB (an academic PPI facilitator) 
and comprising one stroke survivor and two Thalidomide 
Trust beneficiaries; they will shape the research by fully 
participating in quarterly management meetings. The 
group have contributed towards drafting this protocol 
and the plain English abstract. We plan two key work-
shops to ensure that the review findings reach the end 
user in an accessible way. First, a summary writing work-
shop with the PPI advisory group to achieve a clear plain 
language summary and to coproduce a dissemination 
plan targeted at patients and the public. Second, we will 
convene a larger public event on the subject of under-
standing cardiovascular risk, within which the findings of 
this research can be presented in context.
Ethics and dissemination
This is a secondary analysis of anonymised IPD which 
has been obtained from studies where participants have 
already given consent and approval to participate (see 
‘ethics approval and patient consent for publication’ 
declaration). We have sought written permission for 
use of IPD from each individual study lead investigator 
included in the INTERPRESS- IPD Collaboration. We will 
therefore not seek further ethical approval to undertake 
these analyses.
The study will be reported in accordance with the 
Preferred Reporting Items for a Systematic Review 
and Meta- analysis of IPD statement.24 Findings will be 
published as open access articles in high- impact peer- 
reviewed journals and presented at international confer-
ences. We will seek to inform national, European and 
global developers of clinical guidelines, including the 
UK NICE guidance, National Health Service commis-
sioners, the British and Irish Hypertension Society and 
local healthcare providers. We will coproduce a targeted 
dissemination plan for the public and specific patient 
groups and our funding charities, in conjunction with 
the project PPI advisory group. We also plan to undertake 
a public dissemination event for patients, clinicians and 
providers or commissioners regarding the importance of, 
and relationship between, arm and leg BPs and under-
standing the importance of BP measurement in cardio-
vascular risk estimation—the findings from this study will 
be presented. The INTERPRESS- IPD Collaboration is a 
large, international dataset with both arm and leg BPs, 
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and is available for further research activity in this area 
in the future.
DISCUSSION
There are 1.2 million stroke survivors living in the UK 
(State of the Nation Stroke statistics—January 2017: 
The Stroke Association) and 75% of these individuals 
report weakness of upper limb function that interferes 
with activities of daily living.25 Self- monitoring and self- 
titration of BP lowering treatment achieves lower BPs in 
people at high risk of new or recurrent stroke.26 However, 
this is either impossible or difficult for many stroke survi-
vors with significantly impaired upper limb function, and 
for individuals with other barriers to BP measurement in 
the arm. Data suggest a prevalence of 12–13 individuals 
per 100 000 population have upper limb prostheses in 
the UK and Norway.27 28 In addition, over 1700 amputa-
tions higher than wrist level occur annually in the UK.29 
Congenital upper limb deformities are also important; 
for example, the UK Thalidomide Trust has 460 benefi-
ciaries who are now aged in their late 50s. Hypertension 
is a particular concern in this cohort, and over half of 
beneficiaries report upper limb damage.30 Taking these 
data together, we conservatively estimate that between 
6000 and 10 000 adults may be living with significant 
congenital or acquired upper limb loss in the UK. As a 
population, these individuals are in particular need of 
accurate estimates of BP to understand and mitigate their 
cardiovascular risk, stroke being an important avoidable 
consequence.
Thus, barriers to accurate upper arm BP measurement 
exist for a substantial minority of the UK population, 
and corresponding proportions across other countries. 
Whenever circumstances require leg BP measurement, it 
is important to be able to interpret the readings correctly. 
This is the focus of our proposal. Our data originate from 
cohorts across Europe, North America and Africa; there-
fore, we expect our findings to be applicable across the 
globe.
To date, estimates suggest either a minimum difference 
of 15 mm Hg in SBPs between arm and leg, or a conver-
sion factor of ×0.88, as a rule of thumb.5 11 This study aims 
to provide the first evidence- based method for estimating 
individual brachial SBP and cardiovascular risk from leg 
SBP measurements. Our findings will support clinicians 
and patients in detecting and managing hypertension 
more effectively where leg measurements are required.
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